NOVEL BISPECIFIC ANTIGEN BINDING MOLECULES CAPABLE OF SPECIFIC BINDING TO CD40 AND TO FAP

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 11 October 2018 (11.10.2018) WIPO I PCT 0111111010 0111 °nolo OH H ioo IIIII IH oimIE (10) International Publication Nu...

Full description

Saved in:
Bibliographic Details
Main Authors LECLAIR, Stephane, SUM, Eva Carina, RAPP, Moritz, GEORGES, Guy, KLEIN, Christian, DUERR, Harald, UMAÑA, Pablo, BRUENKER, Peter, BUJOTZEK, Alexander, TRUMPELLER, Christine
Format Patent
LanguageEnglish
Published 30.10.2019
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 11 October 2018 (11.10.2018) WIPO I PCT 0111111010 0111 °nolo OH H ioo IIIII IH oimIE (10) International Publication Number WO 2018/185045 Al (51) International Patent Classification: C07K 16/28 (2006.01) A61K 39/00 (2006.01) C07K 16/40 (2006.01) (21) International Application Number: PCT/EP2018/058384 (22) International Filing Date: 03 April 2018 (03.04.2018) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 17164725.8 04 April 2017 (04.04.2017) EP 18158751.0 27 February 2018 (27.02.2018) EP (71) Applicant (for all designated States except US): F. HOFF- MANN-LA ROCHE AG [CH/CH]; Grenzacherstrasse 124, 4070 Basel (CH). (71) Applicant (for US only): HOFFMANN-LA ROCHE INC. [US/US]; Overlook at Great Notch, 150 Clove Road, 8th Floor, Suite 8 - Legal Department, Little Falls, New Jer- sey 07424 (US). (72) Inventors: BRUENKER, Peter; c/o Roche Glycart AG, Wagistrasse 18, 8952 Schlieren (CH). BUJOTZEK, Alexander; Fuerstenrieder Str. 82c, 80686 Muenchen (DE). DUERR, Harald; Gustav-Meyrink-Str. 7a, 82319 Starnberg (DE). GEORGES, Guy; Am Berggraben 11, 82392 Habach (DE). KLEIN, Christian; c/o Roche Glycart AG, Wagistrasse 18, 8952 Schlieren (CH). LECLAIR, Stephane; Schulstr. 12 1 / 4 , 82131 Gauting (DE). RAPP, Moritz; c/o Roche Glycart AG, Wagis- trasse 18, 8952 Schlieren (CH). SUM, Eva Carina; c/o Roche Glycart AG, Wagistrasse 18, 8952 Schlieren (CH). TRUMPFHELLER, Christine; c/o Roche Glycart AG, Wagistrasse 18, 8952 Schlieren (CH). UMASTA, Pablo; c/ o Roche Glycart AG, Wagistrasse 18, 8952 Schlieren (CH). (74) Agent: KLOSTERMEYER RAUBER, Doerte; Gren- zacherstrasse 124, 4070 Basel (CH). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: with international search report (Art. 21(3)) before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h)) with sequence listing part of description (Rule 5.2(a)) (54) Title: NOVEL BISPECIFIC ANTIGEN BINDING MOLECULES CAPABLE OF SPECIFIC BINDING TO CD40 AND TO FAP (57) : The invention relates to novel bispecific antigen binding molecules, comprising (a) at least one antigen binding domain capable of specific binding to CD40, and(b) at least one antigen binding domain capable of specific binding to a target cell antigen,in particular Fibroblast Activation Protein (FAP),and to methods of producing these molecules and to methods of using the same.
Bibliography:Application Number: SG20191108787W